GI 448

Drug Profile

GI 448

Latest Information Update: 30 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Japan
  • Class Macrolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycobacterium avium complex infections

Most Recent Events

  • 14 Feb 2006 No development reported - Preclinical for Mycobacterium avium complex infections in Japan (unspecified route)
  • 28 Feb 2003 Dainabot has merged with Hokuriku Seiyaku to form Abbott Japan
  • 03 Jan 2002 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top